A worldwide biopharmaceutical company.

‘We were holding well-designed studies across a wide dose range that allow us to understand the entire potential of inhibiting this pathway,’ said Mark Genovese, M.D., professor of medication, Stanford University Medical Center, Division of Immunology and Rheumatology. ‘The regularity of response and the overall protection profile of ABT-494 in these two patient populations offer the potential for significant benefit and support advancing this compound into Phase 3 studies. Continue reading